C-erbB-3 in human breast carcinoma: Expression and relation to prognosis and established prognostic indicators

British Journal of Cancer

Volumn 74, Issue 2, 1996, Pages 229-233

  Travis, A ^a   Pinder, S E ^a,e   Robertson, J F R ^a   Bell, J A ^a   Wencyk, P ^a   Gullick, W J ^b   Nicholson, R I ^c   Poller, D N ^d   Blamey, R W ^a   Elston, C W ^a   Ellis, I O ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^e NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Breast carcinoma; C erbB 2; C erbB 3; Growth factor receptor; Immunohistochemistry; Prognostic factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MONOCLONAL ANTIBODY; ONCOPROTEIN; ESTROGEN RECEPTOR;

ADULT; ARTICLE; BREAST TUMOR; CANCER STAGING; CHEMISTRY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; ADVANCED CANCER; BREAST CARCINOMA; CANCER SURVIVAL; GENE EXPRESSION; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MENOPAUSE; ONCOGENE C ERB; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3;

EID: 0029665946     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.342     Document Type: Article

References (24)

1. CARRAWAY KL AND CANTLEY LC. (1994). A new acquaintance for erbB3 and erbB-4: a role for receptor heterodimerisation in growth signalling. Cell, 78, 5-8.
2. CARRAWAY KLI, SLIWKOWSKI MX, AKITA R, PLATKO JV, GUY PM, NUIJENS A, DIAMONTI AJ, VANDLEN RL, CANTLEY LC AND CERIONE RA. (1994). The erbB3 gene product is a receptor for heregulin. J. Biol. Chem., 269, 14303-14306.
3. ELLIS IO, GALEA M, BROUGHTON N, LOCKER A, BLAMEY RW AND ELSTON CW. (1992). Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology, 20, 479-489.
4. ELSTON CW AND ELLIS IO. (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology, 19, 403-410.
5. GASPARINI G, GULLICK WJ, MALUTA S, PALMA PD, CAFFO O, LEONARDI E, BORACCHI P, POZZA F, LEMOINE NR AND BEVILACQUA P. (1994). c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma - an immunocytochemical study. Eur. J. Cancer, 30A, 16-22.
6. GRIMAUX M, ROMAIN S, REMVIKOS Y, MARTIN PM AND MAGDELENAT H. (1989). Prognostic value of epidermal growth factor receptor in node-positive breast cancer. Breast Cancer Res. Treat., 14, 77-90.
7. GULLICK WJ, LOVE SB, WRIGHT C, BARNES DM, GUSTERSON B, HARRIS AL AND ALTMAN DG. (1991). c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br. J. Cancer, 63, 434-438.
8. HAYBITTLE JL, BLAMEY RW, ELSTON CW, JOHNSON J, DOYLE PJ, CAMPBELL FC, NICHOLSON RI AND GRIFFITHS K. (1982). A prognostic index in primary breast cancer. Br. J. Cancer, 45, 361-366.
9. KRAUS MH, FEDI P, STARKS V, MURARO R AND AARONSON SA. (1993). Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells. Proc. Natl Acad. Sci. USA, 90, 2900-2904.
10. LEMOINE NR, BARNES DM, HOLLYWOOD DP, HUGHES CM, SMITH P, DUBLIN E, PRIGENT SA, GULLICK WJ AND HURST HC. (1992). Expression of the ERBB3 gene product in breast cancer. Br. J. Cancer, 66, 1116-1121.
11. LOVEKIN C, ELLIS IO, LOCKER A, ROBERTSON JFR, BELL J, NICHOLSON R, GULLICK WJ, ELSTON CW AND BLAMEY RW. (1991). c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br. J. Cancer, 63, 439-443.
12. NICHOLSON S, WRIGHT C, SAINSBURY JRC, HALCROW P, KELLY P, ANGUS B, FARNDON JR AND HARRIS AL. (1990). Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure. J. Steroid Biochem. Mol. Biol., 37, 811-814.
13. PEREIRA H, PINDER SE, SIBBERING DM, GALEA MH, ELSTON CW, BLAMEY RW, ROBERTSON JFR AND ELLIS IO. (1995). Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology, 27, 219-226.
14. PINDER SE, ELLIS IO, GALEA M, O'ROURKE S, BLAMEY RW AND ELSTON CW. (1994). Pathological prognostic factors in breast cancer. III. Vascular invasion: Relationship with recurrence and survival in a large study with long-term follow-up. Histopathology, 24, 41-47.
15. PLOWMAN GD, GREEN JM, CULOUSCOU JM, CARLTON GW, ROTHWELL VM AND BUCKLEY S. (1993). Heregulin induces tyrosine phosphorylation of HER4/p180 (erbB4). Nature, 366, 473-475.
16. POLLER DN, SPENDLOVE I, BAKER C, CHURCH R, ELLIS IO, PLOWMAN GD AND MAYER RJ. (1992). Production and characterization of a polyclonal antibody to the c-erbB-3 protein: Examination of c-erbB-3 protein expression in adenocarcinomas. J. Pathol., 168, 275-280.
17. PRIGENT SA, LEMOINE NR, HUGHES CM, PLOWMAN GD, SELDEN C AND GULLICK WJ. (1992). Expression of the c-erbB-3 protein in normal human adult and fetal tissues. Oncogene, 7, 1273-1278.
18. RAJKUMAR T, GODEN CSR, LEMOINE NR AND GULLICK WJ. (1993). Expression of the C-erbB-3 protein in gastrointestinal tract tumours determined by monoclonal antibody RTJ1. J. Pathol., 170, 271-278.
19. SAINSBURY JRC, MALCOLM AJ, APPLETON DR, FARNDON JR AND HARRIS AL. (1985). Presence of epidermal growth factor as an indicator of poor prognosis in patients with breast cancer. J. Clin. Pathol., 38, 1225-1228.
20. SAINSBURY JRC, FARNDON JR, NEEDHAM GK, NEEDHAM GK, MALCOLM AJ AND HARRIS AL. (1987). Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet, 1, 1398-1402.
21. SLAMON DJ, CLARK GM, WONG SG, LEVIN WJ, ULLRICH A AND MCGUIRE WL. (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-182.
22. SLIWKOWSKI MX, SCHAEFER G, AKITA RW, LOFGREN JA, FITZPATRICK VD, NUIJENS A, FENDLY BM, CERIONE RA, VANDLEN RL AND CARRAWAY KL. (1994). Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem., 269, 14661-14665.
23. WALKER RA, GULLICK WJ AND VARLEY JM. (1989). An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. Br. J. Cancer, 60, 426-429.
24. WRIGHT C, ANGUS B, NICHOLSON S, SAINSBURY J, CAIRNS J, GULLICK WJ, KELLY P, HARRIS AL AND WILSON HORNE CH. (1989). Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res., 49, 2087-2090.